Latest News
BioArctic and Mesenkia sign research collaboration for glioblastoma antibody project
19 August 2026 - Swedish biopharma company BioArctic AB (STO: BIOA-B), which develops treatments for neurodegenerative diseases, said on Wednesday it has entered a research collaboration with Mesenkia Therapeutics to explore an antibody-based approac...
Sectra to provide Education Portal to Loyalist College for medical imaging training
19 August 2026 - Sectra (STO: SECT B), a medical imaging IT and cybersecurity company, announced on Wednesday that it will provide its cloud-based Education Portal to Loyalist College in Ontario, Canada, giving students access to anonymized diagnosti...
Tolerance Bio licenses clinical-stage IL-7 therapy from NeoImmuneTech
19 August 2026 - Tolerance Bio Inc, a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, announced on Wednesday that it has entered into a licensing agreement wit...
Merck and Moderna report positive Phase 3 melanoma trial results
19 August 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and biotechnology company Moderna Inc (NASDAQ:MRNA) announced on Wednesday that the Phase 3 INTerpath-001 trial of intismeran autogene (...
Scancell announces UK authorisation for Phase 3 melanoma trial
19 August 2026 - Immuno-oncology company Scancell Holdings plc (AIM: SCLP) announced on Wednesday that it has received Clinical Trial Authorization from the UK Medicines and Healthcare Products Regulatory Agency for the Phase 3 registrational trial o...